According to Gram Research analysis, a case series of 7 children with combined malonic and methylmalonic aciduria (CMAMMA) found that all patients had elevated urinary methylmalonic acid levels, with 5 also showing elevated malonic acid. Five children experienced developmental delays despite normal or near-normal blood tests, and five were unresponsive to vitamin B12 therapy. This rare genetic condition, caused by ACSF3 gene mutations, shows that urine testing is more reliable than blood tests for diagnosis.
Researchers studied 7 children with a rare genetic condition called combined malonic and methylmalonic aciduria (CMAMMA), caused by changes in the ACSF3 gene. This condition causes harmful acids to build up in the body. Most children in the study had developmental delays, and standard vitamin B12 treatment didn’t help most of them. The study found that doctors can identify this condition by checking urine and blood tests, even though blood tests sometimes appear normal. Understanding this rare disease helps doctors recognize and treat affected children earlier.
Key Statistics
A 2026 case series of 7 children with CMAMMA found that all 7 patients had elevated urinary methylmalonic acid levels, with 5 also showing elevated malonic acid, yet blood acylcarnitine profiles were normal in most cases.
In a 2026 analysis of 7 children with ACSF3-related CMAMMA, 5 patients (71%) showed developmental delays and 5 patients (71%) were unresponsive to vitamin B12 therapy, indicating this condition requires specialized treatment approaches.
A 2026 case series identified 11 ACSF3 gene variants in 7 children with CMAMMA, including 2 novel variants (c.785C>T and c.889T>A) never previously reported in medical literature.
The Quick Take
- What they studied: A rare genetic disease where the body can’t properly break down certain acids, causing them to build up in urine and potentially harm development
- Who participated: Seven children (6 boys and 1 girl) ranging from infants to 8 years old, all diagnosed with CMAMMA at a children’s hospital in Shanghai between 2021 and 2025
- Key finding: All 7 children had high levels of methylmalonic acid in their urine, and 5 of them also had high malonic acid levels. Five children showed developmental delays, but surprisingly, standard blood tests often appeared normal
- What it means for you: If your child has unexplained developmental delays or developmental concerns, doctors should check urine acid levels even if blood tests seem normal. This condition is rare but treatable with early detection
The Research Details
This was a case series study, meaning researchers looked back at medical records of 7 children who had already been diagnosed with CMAMMA. The children were treated at a specialized hospital department between December 2021 and November 2025. Doctors collected information about when symptoms started, what symptoms appeared, and test results over time.
The researchers used three main types of tests to diagnose and understand the condition. First, they used tandem mass spectrometry (a machine that identifies different molecules in blood) to measure special fats called acylcarnitines. Second, they used gas chromatography-mass spectrometry (another specialized machine) to measure acids in urine. Third, they used genetic testing (Sanger sequencing or next-generation sequencing) to identify the specific gene changes causing the disease.
This approach allowed doctors to see the complete picture of how the disease appears in real children and what genetic changes cause it.
This study is important because CMAMMA is extremely rare, so most doctors have never seen it. By carefully documenting 7 cases, researchers created a guide for recognizing the disease. The study also identified two new genetic variations never reported before, which helps scientists understand how the ACSF3 gene works and what happens when it’s damaged.
This is a small study of only 7 children from one hospital, so the findings may not apply everywhere. However, the researchers carefully documented everything and used reliable laboratory tests. The study’s strength is that it provides detailed real-world information about how this rare disease actually appears in children. The main limitation is that with such a small number of patients, we can’t make broad predictions about all children with this condition.
What the Results Show
All seven children had abnormally high levels of methylmalonic acid in their urine, which is the hallmark sign of this disease. Five of the seven children also had high malonic acid levels. Interestingly, when doctors checked the children’s blood using standard tests, the results usually appeared normal or only slightly abnormal—even though the urine showed clear problems. This is important because it means doctors can’t rely only on blood tests to diagnose this condition.
Five of the seven children experienced developmental delays (slower learning and physical development than typical for their age). One child also had seizures (sudden electrical disturbances in the brain), and another had low muscle tone. However, one child developed completely normally despite having the same genetic condition, showing that this disease affects different children in very different ways.
When doctors tried treating five of the children with vitamin B12 (a common treatment for similar conditions), it didn’t help. This suggests that CMAMMA needs different treatment approaches than related diseases. The genetic testing found 11 different variations in the ACSF3 gene, including two never seen before in medical literature.
The study found significant variation in how the disease progresses. Six of the seven children didn’t experience a severe metabolic crisis during infancy or early childhood, which is unusual for this type of genetic disease. However, follow-up visits showed that five children had severe or borderline developmental delays, one developed normally, and sadly, one child died. This shows that even though the disease may not cause immediate crisis in infancy, it can have serious long-term effects on brain development.
This is one of the first detailed studies of CMAMMA caused by ACSF3 gene changes. Previous research on similar acid storage diseases suggested that blood tests would show clear abnormalities, but this study found that assumption isn’t always true for CMAMMA. The finding that vitamin B12 doesn’t help most patients differs from related conditions like methylmalonic aciduria caused by other genetic problems, where B12 is often effective.
The study included only 7 children from one hospital in China, so these findings may not apply to all children worldwide or to different populations. With such a small group, we can’t predict exactly how common different symptoms are or what the long-term outlook will be for all patients. The study is also retrospective, meaning researchers looked back at old medical records rather than following children forward in time, which can miss some details. Finally, because this is such a rare disease, we need studies from more hospitals and countries to fully understand it.
The Bottom Line
If your child has unexplained developmental delays, seizures, or low muscle tone, ask your doctor about checking urine organic acids even if blood tests appear normal (moderate confidence). If your child is diagnosed with CMAMMA, work with a metabolic specialist rather than a general pediatrician, as this requires specialized knowledge (high confidence). Vitamin B12 supplementation alone is unlikely to be effective for CMAMMA, so discuss alternative treatments with your doctor (moderate confidence).
Parents of children with unexplained developmental delays should know about this condition. Pediatricians and genetic specialists should consider CMAMMA when standard tests don’t explain a child’s symptoms. Children with confirmed CMAMMA need specialized metabolic care. This research is less relevant for adults or children without developmental concerns.
Developmental delays may become apparent between ages 1-8 years. Early diagnosis through urine testing can help doctors start appropriate management sooner. However, even with treatment, some children show persistent developmental challenges, so realistic expectations are important.
Frequently Asked Questions
What causes combined malonic and methylmalonic aciduria in children?
CMAMMA is caused by mutations in the ACSF3 gene, which prevents the body from properly breaking down certain acids. These acids then build up in the urine and can affect brain development. A 2026 study identified 11 different ACSF3 mutations in just 7 children.
How do doctors diagnose CMAMMA if blood tests are normal?
Doctors should check urine organic acids using specialized testing (gas chromatography-mass spectrometry), not just blood tests. A 2026 case series found that all 7 children had abnormal urine acid levels even when blood tests appeared normal, making urine testing essential for diagnosis.
Does vitamin B12 help children with CMAMMA?
No, vitamin B12 is ineffective for most CMAMMA cases. In a 2026 study of 7 children, 5 patients (71%) showed no response to vitamin B12 therapy, indicating this condition requires different treatment approaches than related acid storage diseases.
What are the long-term outcomes for children with CMAMMA?
Outcomes vary significantly. A 2026 case series of 7 children found that 5 experienced developmental delays, 1 developed normally, and 1 died. This shows the disease has unpredictable effects on brain development and requires close medical monitoring.
At what age do symptoms of CMAMMA typically appear?
In a 2026 study of 7 children, symptoms appeared between ages 0.4 to 8 years, with a median age of 1 year. Interestingly, 6 of 7 children didn’t experience acute metabolic crisis in infancy, though developmental delays emerged later.
Want to Apply This Research?
- Track developmental milestones (first words, sitting up, walking) and any seizures or muscle tone changes with specific dates. Note any changes after starting new treatments or dietary changes.
- If your child is diagnosed, use the app to schedule regular follow-up appointments with metabolic specialists and document lab results (urine acid levels, blood tests) over time to monitor disease progression.
- Create a long-term tracking system for developmental progress, seizure frequency (if applicable), and lab values. Share this data with your medical team at each visit to help guide treatment decisions.
This article describes a rare genetic condition requiring specialized medical care. The findings are based on a small case series of 7 children from one hospital and may not apply universally. If you suspect your child has CMAMMA or any metabolic disorder, consult with a pediatric metabolic specialist or geneticist for proper diagnosis and treatment. Do not use this information to self-diagnose or replace professional medical advice. Vitamin B12 or other treatments should only be started under medical supervision.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.